Tag - FREQ

Feature

Korro Bio merger and financing to fuel RNA editing technology

Korro Bio’s reverse merger with Frequency Therapeutics (NASDAQ:FREQ), which is expected to close in the 2023 fourth quarter, and concurrent financing are expected to build up an investor base to bankroll Korro’s...

September 26, 2023

Developments

Frequency Therapeutics reports positive results from hearing loss study

Frequency Therapeutics (NASDAQ:FREQ) reported results from its Phase 2a clinical study of FX-322 for the treatment of sensorineural hearing loss (SNHL). The study follows a Phase 1/2 trial that demonstrated...

September 14, 2020

Developments

Frequency Therapeutics gets FDA fast track designation for FX-322; begins Phase 2a study dosing

In addition to receiving FDA fast track designation for FX-322, Frequency Therapeutics (NASDAQ:FREQ) initiated dosing in a Phase 2a clinical study of the drug candidate for the treatment of sensorineural hearing loss...

October 11, 2019

Tag - FREQ

Korro Bio merger and financing to fuel RNA editing technology

Frequency Therapeutics reports positive results from hearing loss study

Frequency Therapeutics gets FDA fast track designation for FX-322; begins Phase 2a study dosing

General

More